Top

Published in:

01-08-2012 | Editorial

Online First service, a further step forward

Author: The Editors

Published in: Clinical and Translational Oncology | Issue 8/2012

Excerpt

Clinical and Translational Oncology has accomplished a substantial increase in the number of manuscripts received for evaluation. However, constraints of space make it impossible to publish all the submitted papers that are of sufficient quality and interest. Our commitment with high quality translational and clinical research remains unchanged, and papers accepted for publication must meet stringent requirements of scientific breadth and impact to the field as well as high scientific quality, originality and priority. Manuscripts that do not meet all of these criteria are not acceptable for publication. The present number of submissions is much greater than the number of articles that we can publish, and it also exceeds the number of manuscripts that can be carefully reviewed in a timely manner. …

Kravitz RL, Franks P, Feldman MD et al (2010) Editorial peer reviewers’ recommendations at a general medical journal: are they reliable and do editors care? PLoS One 5(4):e10072. doi:10.1371/journal.pone.0010072 PubMedCrossRef

Harley D, Krzys Acord S (2011) Peer review in academic promotion and publishing: its meaning, locus, and future. Center for Studies in Higher Education, UC Berkeley. http://escholarship.org/uc/item/1xy148c8

Suls J, Martin R (2009) The air we breathe. A critical look at the practices and alternatives in the peer-review process. Perspect Psychol Sci 4:40–50. doi:10.1111/j.1745-6924.2009.01105.x CrossRef

(2006) Overview: nature’s peer review trial. Nature. doi:10.1038/nature05535

Title: Online First service, a further step forward
Author: The Editors
Publication date: 01-08-2012
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 8/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0852-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2012

Fifty percent patients avoid whole brain radiotherapy: stereotactic radiotherapy for multiple brain metastases. A retrospective analysis of a single center

Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II–III rectal cancer

Hereditary pancreatic cancer: molecular bases and their application in diagnosis and clinical management. A guideline of the TTD group

Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients

BIK/NBK gene as potential marker of prognostic and therapeutic target in breast cancer patients

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer